Back to Screener

Healthcare

argenx SE(ARGX)

Live Price

Offline

$876.88

-1.72% today

1Y Change

+59.18%

Window

Jun 25, 2025 โ†’ Jun 17, 2026

Market Cap
$50.01B
Revenue Growth
+90.1%
EPS Growth
+51.9%
Dividend Yield
0.0%

Coverage: 246 bars ยท Jun 25, 2025 โ†’ Jun 17, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

argenx SE (ARGX) is a Healthcare stock with a market cap of $50.01B. The stock last traded around $876.88 and up 59.2% across the available one-year price window (Jun 25, 2025 โ†’ Jun 17, 2026). Baseline metrics include revenue growth of +90.1%, EPS growth of +51.9%, a dividend yield of 0.0%. What stands out right now is revenue +90.1%, EPS +51.9%, free cash flow +659.0% with operating margin 25.6% and ROIC 11.7%. Valuation already assumes a fairly strong business story at P/E 44.0 and price/sales 14.8. Stock Foundry combines ARGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+90.1% vs +7.6% peer median

Operating Margin

Above sector median

+25.6% vs +19.4% peer median

P/E

Above sector median

44.0 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report landed above expectations

Q2 2026 was reported on May 7, 2026 with an EPS surprise of +12.2%.

The operating story is still moving forward

Revenue is running at +90.1% and EPS at +51.9%, with operating margin around 25.6%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged +0.8% over the next 5 trading days and finished higher after 2 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
Q2 2026
May 7, 2026
+12.2%-0.7%+4.4%+13.2%
Q1 2026
Feb 26, 2026
+30.6%-0.6%-5.6%-10.2%
Q4 2025
Oct 30, 2025
+25.4%-0.2%+3.7%+11.2%

Benchmark Edge

ARGX vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

ARGX

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

ARGX Max Drawdown

-28.58%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for ARGX and SPY.

Calendar-year return history is still loading or unavailable.
AR

Company Overview

argenx SE

Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
44.0
EV/EBITDA
48.2
Price/Sales
14.8
Price/Book
6.8

Growth

Revenue
+90.1%
EPS
+51.9%
Free Cash Flow
+659.0%

Profitability

Gross Margin
89.0%
Operating Margin
25.6%
Net Margin
33.4%
ROE
16.8%
ROIC
11.7%

Balance Sheet

Debt/Equity
0.01
Current Ratio
5.23

Earnings Reports

๐Ÿ“… Last reportedMay 7, 2026Q2
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
Q2
May 7, 26
โœ“
4.70
Est 4.19
+12.2%
โ€”
Est โ€”
โ€”
Q1
Feb 26, 26
โœ“
6.79
Est 5.20
+30.6%
โ€”
Est โ€”
โ€”
Q4
Oct 30, 25
โœ“
4.44
Est 3.54
+25.4%
โ€”
Est โ€”
โ€”
Q3
Jul 31, 25
โœ“
3.26
Est 2.61
+24.9%
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.